Granulocyte colony-stimulating factor increases CD4+ T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: results from a randomized, placebo-controlled trial

H Aladdin; H Ullum; S. Dam Nielsen; C Espersen; L Mathiesen; T L Katzenstein; J Gerstoft; P Skinhoj; Bente Klarlund Pedersen

doi:10.1086/315305

Granulocyte colony-stimulating factor increases CD4+ T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: results from a randomized, placebo-controlled trial

H Aladdin, H Ullum, S. Dam Nielsen, C Espersen, L Mathiesen, T L Katzenstein, J Gerstoft, P Skinhoj, Bente Klarlund Pedersen

Institut for Klinisk Medicin

28 Citationer (Scopus)

Abstract

Thirty human immunodeficiency virus (HIV)-infected patients with CD4+ T cell counts <350 cells/mm3 who had received stable, highly active antiretroviral therapy (HAART) for at least 24 weeks were randomized to receive either placebo or granulocyte colony-stimulating factor (G-CSF; 0.3 mg/mL 3 times a week) for 12 weeks. Blood samples were collected at specified time points. G-CSF treatment enhanced the total lymphocyte count (P=.002) and increased CD3+ (P=.005), CD4+ (P=.03), and CD8+ (P=.004) T cell counts as well as numbers of CD3-CD16+CD56+ NK cells (P=.001). The increases in CD4+ and CD8+ cell counts resulted from increases in CD45RO+ memory T cells and cells expressing the CD38 activation marker. Lymphocyte proliferative responses to phytohemagglutinin and Candida antigen decreased, whereas NK cell activity and plasma HIV RNA did not change during G-CSF treatment. After 24 weeks, all immune parameters had returned to baseline values. This study suggests that G-CSF treatment of HIV-infected patients receiving stable HAART increases the concentration of CD4+, CD8+, and NK cells without inducing changes in the virus load.

Originalsprog	Engelsk
Tidsskrift	The Journal of Infectious Diseases
Vol/bind	181
Udgave nummer	3
Sider (fra-til)	1148-52
Antal sider	5
ISSN	0022-1899
DOI	https://doi.org/10.1086/315305
Status	Udgivet - mar. 2000

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1086/315305

Fingeraftryk

Dyk ned i forskningsemnerne om 'Granulocyte colony-stimulating factor increases CD4+ T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: results from a randomized, placebo-controlled trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Aladdin, H., Ullum, H., Dam Nielsen, S., Espersen, C., Mathiesen, L., Katzenstein, T. L., Gerstoft, J., Skinhoj, P., & Pedersen, B. K. (2000). Granulocyte colony-stimulating factor increases CD4+ T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: results from a randomized, placebo-controlled trial. The Journal of Infectious Diseases, 181(3), 1148-52. https://doi.org/10.1086/315305

Granulocyte colony-stimulating factor increases CD4+ T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy : results from a randomized, placebo-controlled trial. / Aladdin, H; Ullum, H; Dam Nielsen, S. et al.

I: The Journal of Infectious Diseases, Bind 181, Nr. 3, 03.2000, s. 1148-52.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Aladdin, H, Ullum, H, Dam Nielsen, S, Espersen, C, Mathiesen, L, Katzenstein, TL, Gerstoft, J, Skinhoj, P & Pedersen, BK 2000, 'Granulocyte colony-stimulating factor increases CD4+ T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: results from a randomized, placebo-controlled trial', The Journal of Infectious Diseases, bind 181, nr. 3, s. 1148-52. https://doi.org/10.1086/315305

Aladdin H, Ullum H, Dam Nielsen S, Espersen C, Mathiesen L, Katzenstein TL et al. Granulocyte colony-stimulating factor increases CD4+ T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: results from a randomized, placebo-controlled trial. The Journal of Infectious Diseases. 2000 mar.;181(3):1148-52. doi: 10.1086/315305

@article{2946a0a2068040bea24c4327e1e3cf70,

title = "Granulocyte colony-stimulating factor increases CD4+ T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: results from a randomized, placebo-controlled trial",

abstract = "Thirty human immunodeficiency virus (HIV)-infected patients with CD4+ T cell counts <350 cells/mm3 who had received stable, highly active antiretroviral therapy (HAART) for at least 24 weeks were randomized to receive either placebo or granulocyte colony-stimulating factor (G-CSF; 0.3 mg/mL 3 times a week) for 12 weeks. Blood samples were collected at specified time points. G-CSF treatment enhanced the total lymphocyte count (P=.002) and increased CD3+ (P=.005), CD4+ (P=.03), and CD8+ (P=.004) T cell counts as well as numbers of CD3-CD16+CD56+ NK cells (P=.001). The increases in CD4+ and CD8+ cell counts resulted from increases in CD45RO+ memory T cells and cells expressing the CD38 activation marker. Lymphocyte proliferative responses to phytohemagglutinin and Candida antigen decreased, whereas NK cell activity and plasma HIV RNA did not change during G-CSF treatment. After 24 weeks, all immune parameters had returned to baseline values. This study suggests that G-CSF treatment of HIV-infected patients receiving stable HAART increases the concentration of CD4+, CD8+, and NK cells without inducing changes in the virus load.",

keywords = "Adult, Aged, CD4 Lymphocyte Count, Female, Granulocyte Colony-Stimulating Factor, HIV Infections, Humans, Interleukin-2, Killer Cells, Natural, Lymphocyte Activation, Male, Middle Aged, Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't",

author = "H Aladdin and H Ullum and {Dam Nielsen}, S. and C Espersen and L Mathiesen and Katzenstein, {T L} and J Gerstoft and P Skinhoj and Pedersen, {Bente Klarlund}",

year = "2000",

month = mar,

doi = "10.1086/315305",

language = "English",

volume = "181",

pages = "1148--52",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Granulocyte colony-stimulating factor increases CD4+ T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy

T2 - results from a randomized, placebo-controlled trial

AU - Aladdin, H

AU - Ullum, H

AU - Dam Nielsen, S.

AU - Espersen, C

AU - Mathiesen, L

AU - Katzenstein, T L

AU - Gerstoft, J

AU - Skinhoj, P

AU - Pedersen, Bente Klarlund

PY - 2000/3

Y1 - 2000/3

N2 - Thirty human immunodeficiency virus (HIV)-infected patients with CD4+ T cell counts <350 cells/mm3 who had received stable, highly active antiretroviral therapy (HAART) for at least 24 weeks were randomized to receive either placebo or granulocyte colony-stimulating factor (G-CSF; 0.3 mg/mL 3 times a week) for 12 weeks. Blood samples were collected at specified time points. G-CSF treatment enhanced the total lymphocyte count (P=.002) and increased CD3+ (P=.005), CD4+ (P=.03), and CD8+ (P=.004) T cell counts as well as numbers of CD3-CD16+CD56+ NK cells (P=.001). The increases in CD4+ and CD8+ cell counts resulted from increases in CD45RO+ memory T cells and cells expressing the CD38 activation marker. Lymphocyte proliferative responses to phytohemagglutinin and Candida antigen decreased, whereas NK cell activity and plasma HIV RNA did not change during G-CSF treatment. After 24 weeks, all immune parameters had returned to baseline values. This study suggests that G-CSF treatment of HIV-infected patients receiving stable HAART increases the concentration of CD4+, CD8+, and NK cells without inducing changes in the virus load.

AB - Thirty human immunodeficiency virus (HIV)-infected patients with CD4+ T cell counts <350 cells/mm3 who had received stable, highly active antiretroviral therapy (HAART) for at least 24 weeks were randomized to receive either placebo or granulocyte colony-stimulating factor (G-CSF; 0.3 mg/mL 3 times a week) for 12 weeks. Blood samples were collected at specified time points. G-CSF treatment enhanced the total lymphocyte count (P=.002) and increased CD3+ (P=.005), CD4+ (P=.03), and CD8+ (P=.004) T cell counts as well as numbers of CD3-CD16+CD56+ NK cells (P=.001). The increases in CD4+ and CD8+ cell counts resulted from increases in CD45RO+ memory T cells and cells expressing the CD38 activation marker. Lymphocyte proliferative responses to phytohemagglutinin and Candida antigen decreased, whereas NK cell activity and plasma HIV RNA did not change during G-CSF treatment. After 24 weeks, all immune parameters had returned to baseline values. This study suggests that G-CSF treatment of HIV-infected patients receiving stable HAART increases the concentration of CD4+, CD8+, and NK cells without inducing changes in the virus load.

KW - Adult

KW - Aged

KW - CD4 Lymphocyte Count

KW - Female

KW - Granulocyte Colony-Stimulating Factor

KW - HIV Infections

KW - Humans

KW - Interleukin-2

KW - Killer Cells, Natural

KW - Lymphocyte Activation

KW - Male

KW - Middle Aged

KW - Clinical Trial

KW - Journal Article

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

U2 - 10.1086/315305

DO - 10.1086/315305

M3 - Journal article

C2 - 10720544

SN - 0022-1899

VL - 181

SP - 1148

EP - 1152

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 3

ER -